{"id":4855,"date":"2025-07-01T10:10:36","date_gmt":"2025-07-01T00:10:36","guid":{"rendered":"\/eu-uk\/?p=4855"},"modified":"2025-07-01T10:10:36","modified_gmt":"2025-07-01T00:10:36","slug":"orthocell-achieves-a-record-2-73m-in-revenue-for-june-quarter","status":"publish","type":"post","link":"\/eu-uk\/blog\/2025\/07\/01\/orthocell-achieves-a-record-2-73m-in-revenue-for-june-quarter\/","title":{"rendered":"Orthocell Achieves a Record $2.73m in Revenue for June Quarter"},"content":{"rendered":"<p>Orthocell has announced record quarterly revenue of $2.73 million for the June quarter &#8211; our fifth consecutive quarter of record revenue growth.<\/p>\n<p>This outstanding 22.8% increase demonstrates the exceptional market response to Orthocell\u2019s flagship products, Striate+\u2122 and Remplir\u2122. This was achieved before any contribution from US Remplir\u2122 sales, which are expected to ramp up during the first half of FY26.<\/p>\n<p><strong>Key Highlights:<\/strong><\/p>\n<ul>\n<li>Record quarterly revenue of $2.73 million (up 22.8% from March quarter)<\/li>\n<li>Fifth consecutive quarter of record revenue<\/li>\n<li>Compound Quarterly Growth Rate of 9.5% over the last 3 years<\/li>\n<li>Strong balance sheet with ~A$28.5 million cash and no debt<\/li>\n<li>Remplir\u2122 now used by &gt;200 surgeons across &gt;165 hospitals in Australia<\/li>\n<li>US market expansion accelerating with 14 specialist distributors across 25 states<\/li>\n<\/ul>\n<p>With FDA clearance achieved and first US surgery completed, Orthocell is perfectly positioned to capture significant market share in the US$1.6 billion nerve repair market.<\/p>\n<p><strong><a href=\"https:\/\/bit.ly\/OCC-June-Quarter\">Click to read the ASX release.<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orthocell has announced record quarterly revenue of $2.73 million for the June quarter &#8211; our fifth consecutive quarter of record revenue growth.<\/p>\n","protected":false},"author":2,"featured_media":4856,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-4855","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news"],"aioseo_notices":[],"_links":{"self":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/comments?post=4855"}],"version-history":[{"count":1,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4855\/revisions"}],"predecessor-version":[{"id":4857,"href":"\/eu-uk\/wp-json\/wp\/v2\/posts\/4855\/revisions\/4857"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/media\/4856"}],"wp:attachment":[{"href":"\/eu-uk\/wp-json\/wp\/v2\/media?parent=4855"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/categories?post=4855"},{"taxonomy":"post_tag","embeddable":true,"href":"\/eu-uk\/wp-json\/wp\/v2\/tags?post=4855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}